[
  {
    "ts": null,
    "headline": "Regeneron Launches $200 Million Donation Matching Program to Support Vision Care",
    "summary": "Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the best S&P 500 stocks with huge upside potential. On June 24, Regeneron Pharmaceuticals announced a new and pioneering donation matching program to support Good Days, which is an independent national non-profit charitable organization. The initiative is designed to support Good Days’ Retinal Vascular and Neovascular Disease Fund. […]",
    "url": "https://finnhub.io/api/news?id=45f72f52b5e46c06c7aee6d346d54b9aa34389cfe72e99bdec5458c7223ac58b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750884372,
      "headline": "Regeneron Launches $200 Million Donation Matching Program to Support Vision Care",
      "id": 135536883,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the best S&P 500 stocks with huge upside potential. On June 24, Regeneron Pharmaceuticals announced a new and pioneering donation matching program to support Good Days, which is an independent national non-profit charitable organization. The initiative is designed to support Good Days’ Retinal Vascular and Neovascular Disease Fund. […]",
      "url": "https://finnhub.io/api/news?id=45f72f52b5e46c06c7aee6d346d54b9aa34389cfe72e99bdec5458c7223ac58b"
    }
  },
  {
    "ts": null,
    "headline": "CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential?",
    "summary": "CRSP edges ahead of NTLA with the only approved CRISPR therapy, stronger pipeline breadth and recent stock gains.",
    "url": "https://finnhub.io/api/news?id=80e91f10b910bf0a4c9b52a5eac8b15b7722faeffb1530fc27a57548314eaea2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750860180,
      "headline": "CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential?",
      "id": 135527467,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "CRSP edges ahead of NTLA with the only approved CRISPR therapy, stronger pipeline breadth and recent stock gains.",
      "url": "https://finnhub.io/api/news?id=80e91f10b910bf0a4c9b52a5eac8b15b7722faeffb1530fc27a57548314eaea2"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals Stock May Be Worth Buying Again - Rating Upgrade",
    "summary": "Regeneron Pharmaceuticals Stock May Be Worth Buying Again - Rating Upgrade",
    "url": "https://finnhub.io/api/news?id=a3823b4eab8a3b599bb3f96eadd46ece5ce0a8a1b93cde82204d858cec42fb25",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750843166,
      "headline": "Regeneron Pharmaceuticals Stock May Be Worth Buying Again - Rating Upgrade",
      "id": 135525019,
      "image": "",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=a3823b4eab8a3b599bb3f96eadd46ece5ce0a8a1b93cde82204d858cec42fb25"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron: Negative Scenario Is Being Realized (Rating Downgrade)",
    "summary": "Regeneron: Negative Scenario Is Being Realized (Rating Downgrade)",
    "url": "https://finnhub.io/api/news?id=6a7cfdea50e61a70489119ef19745416268ab7d348e1adbba0dc401018f17057",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750839401,
      "headline": "Regeneron: Negative Scenario Is Being Realized (Rating Downgrade)",
      "id": 135524416,
      "image": "",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=6a7cfdea50e61a70489119ef19745416268ab7d348e1adbba0dc401018f17057"
    }
  }
]